Boston Scientific Earnings Preview: What to Expect

Core Insights - Boston Scientific Corporation (BSX) is a leading medical device company with a market cap of $140.4 billion, focusing on various interventional medical specialties globally [1] Financial Performance - Analysts expect BSX to report a profit of $0.78 per share for Q4 2025, reflecting an 11.4% increase from $0.70 per share in the same quarter last year [2] - For the full fiscal year 2025, BSX is projected to achieve an EPS of $3.04, which is a 21.1% increase from $2.51 in fiscal 2024 [3] - The EPS is anticipated to rise further to $3.45 in fiscal 2026, marking a year-over-year growth of 13.5% [3] Stock Performance - Over the past 52 weeks, BSX stock has increased by 7.2%, underperforming the S&P 500 Index, which gained 17.1%, and the Health Care Select Sector SPDR Fund, which returned 14.3% [4] - Following the Q3 results announcement on October 22, 2025, BSX shares rose by 4%, with an adjusted EPS of $0.75 exceeding Wall Street's expectation of $0.71 and revenue reaching $5.1 billion, surpassing forecasts of $5 billion [5] Analyst Ratings - The consensus opinion among analysts is bullish, with a "Strong Buy" rating for BSX stock; 26 out of 31 analysts recommend a "Strong Buy," while three suggest a "Moderate Buy" and two give a "Hold" [6] - The average analyst price target for BSX is $126.80, indicating a potential upside of 28.5% from current levels [6]